FWD1802 Investigator Symposium Successfully Concluded
On October 19, 2025, the Investigator Symposium for FWD1802 - a next-generation oral selective estrogen receptor degrader (oral SERD) for treating ER+/HER2- breast cancer, developed by Forward Pharma - was successfully held in Wuhan Optics Valley. This event was also co-sponsored by Biolake, Wuhan Optics Valley. Professor Zhang Jian, chief physician of the Department of Medical Oncology at Fudan University Shanghai Cancer Center, PhD supervisor, and executive director of the Phase I Clinical Trial Unit at Fudan University Shanghai Cancer Center, was the leading principle investigator of FWD1802 China study, gathered with 66 breast cancer experts and researchers from 28 research centers nationwide for this significant event. Professor Zhang Jian and Dr. Zhu Chenggang, co-founder of Forward Pharma, jointly delivered the opening remarks.
Figure 1: Address by Professor Zhang Jian
This symposium provided an open platform for participating investigators to engage in in-depth discussions focused on the FWD1802 clinical trial. Key topics covered included the drug's mechanism of action, clinical data, and safety management measures. The aim was to enhance investigators' understanding of FWD1802's pharmacological characteristics, thoroughly explore the critical points and challenges in the scientific implementation of its clinical studies, and generate new insights for optimizing clinical treatment strategies. These efforts will ensure the smooth progression of subsequent clinical trials.
At the outset of the conference, Forward Pharma and Quintiles presented the FWD1802 study protocol to attending investigators and reported clinical research data. Guided by Professor Zhang Jian's expert commentary, investigators engaged in in-depth discussions focusing on critical issues within the study protocol and implementation process. Together with Forward Pharm, they explored potential therapeutic breakthroughs. Professor Zhang Jian's insights on safety management measures for combination therapies provided valuable references for all the investigators. The following collaborative discussions from the investigators brought the conference to its climax. The perspectives and insights shared by the investigators, grounded in their extensive research experience and innovative thinking, offered practical, clinically relevant guidance for Forward Pharma's development and innovation in the next phase. These discussions also help establishing a general model for advancing Forward Pharma clinical trial development capabilities.
At the conclusion of the conference, Professor Zhang Jian, the leading investigator of FWD1802, and Dr. Wang Joy, Vice President of Corporate Operations at Forward Pharma, delivered closing remarks summarizing the meeting. Together, they outlined the potential prospects for FWD1802 in both monotherapy and combination therapy in the future. All investigators and research teams were encouraged to work together diligently to accelerate the completion of clinical studies for this novel SERD, thereby bringing benefits to a broader patient population. The conference concluded successfully amid enthusiastic applause.
Figure 2: Professor Zhang Jian shares insights and engages in discussions with participating investigators.
FWD1802 is a third-generation oral selective estrogen receptor degrader (oral SERD) for breast cancer endocrine therapy. FWD1802 acts as a competitive antagonist of the estrogen receptor (ER), inducing conformational changes in the ER protein and promoting its degradation, as well as ER antagonism, thereby as a complete ER antabonist, demonstrating superior in vitro and in vivo efficacy compared to other oral SERDs under development. It remains effective against ESR1 mutations emerging after standard endocrine therapy. This positions FWD1802 not only as a treatment option for ESR1-mutated breast cancer resistant to conventional endocrine therapy but also as a potential replacement for existing endocrine regimens, establishing it as a new standard endocrine treatment. Additionally, FWD1802 demonstrates favorable in vivo bioavailability, enabling convenient oral administration for patients in clinical settings.
Forward Pharma remains steadfastly committed to creating clinical value through pharmaceutical innovation, with a mission to deliver treatment solutions for major disease areas. The successful convening of the FWD1802 Investigator Symposium not only showcased Forward Pharma R&D capabilities and innovative achievements in breast cancer treatment but also laid a solid foundation and charted a clear path for advancing the subsequent clinical studies of FWD1802. By collaborating with breast cancer KOLs, Forward Pharma is advancing clinical development and striving to bring greater clinical benefits to breast cancer patients!
About Forward Pharmaceuticals
Forward Pharmaceuticals is an innovative biotech company with an independent R&D pipeline spanning target validation, drug discovery, early-stage development, translational medicine research, preclinical studies, clinical development, and regulatory affairs. The company has established international R&D and operation teams in Nanshan District, Shenzhen; Pudong, Shanghai; and Optics Valley, Wuhan. Forward Pharmaceuticals has established proprietary drug discovery platforms with core intellectual property rights and a distinctive drug R&D innovation system since its inception. Building upon this foundation, the company has developed a product pipeline matrix featuring over 10 innovative drugs, with indications spanning multiple solid tumors and autoimmune diseases.
Related Reading